check_circleStudy Completed

Maxillary Sinusitis

Trial to evaluate time to symptom relief and elimination of infecting bacteria in treating sinusitis with Avelox

Trial purpose

This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.

Key Participants Requirements

Sex

Both

Age

18 Years
  • - Clinical diagnosis of acute sinusitis with signs and symptoms present for >7 days but < 28 days as defined by A), radiographic, and B) clinical criteria, as follows:a. The presence of 1 or more of the following on a radiographic paranasal sinus film (Waters' view) or limited CT scan:** evidence of air-fluid levels** opacification. The presence of at least one major and one minor symptom as defined in the list below:** Major Symptoms*** Purulent anterior or posterior nasal discharge*** Unilateral moderate or severe facial pain or malar tenderness** Minor Symptoms*** Cough or frequent throat clearing*** Frontal headache*** Halitosis*** Fever (oral > 38.0°C/100.4°F, tympanic > 38.5°C/101.2°F)*** Purulent secretions obtained via middle meatus secretion sampling using nasal endoscopic technique; the specimen sent for Gram stain, culture and susceptibility testing prior to initiation of antimicrobial therapy
  • - History of chronic sinusitis defined as greater than four weeks of continuous symptoms (patients with history of sinus surgery may be included; patients with recurrent sinusitis may be included)
    - Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses- Received systemic antibacterial therapy likely to be effective in sinusitis for more than 24 hours within 7 days of enrollment- A requirement for concomitant systemic antibacterial therapy with agents other than those specified in this protocol- Known immunodeficiency diseases including AIDS (CD4 <200)- On topical nasal or systemic corticosteroids, unless they have been on a stable dose for > 4 weeks prior to enrollment- History of allergy to quinolone antibiotics or related compounds- Pregnant or breast feeding- Of childbearing potential in whom pregnancy cannot be excluded by a negative pregnancy test and who are not using reliable barrier method of contraception
    - Received an investigational drug in the past 30 days- Unable to take oral medication- Known to have congenital or sporadic syndromes of QTc prolongation or receiving concomitant medication reported to increase the QTc interval (e.g. amiodarone, sotalol, disopyramide, quinidine, procainamide, terfenadine)
    - End stage liver cirrhosis (class Child-Pugh C)- Severe renal impairment requiring dialysis
    - Previous history of tendinopathy associated with quinolones- Any symptoms that suggest that the patient's current illness is allergic rhinitis (e.g., repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis
    - Diagnosis of rapidly fatal illness with a life expectance of less than 6 months- Previously enrolled in this clinical study- Uncorrected hypokalaemia

Trial summary

Enrollment Goal
192
Trial Dates
June 2004 - January 2005
Phase
Phase 4
Could I Receive a placebo
No
Products
Avelox (Moxifloxacin hydrochloride, BAY12-8039)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Buenos Aires (Capital Federal), 1416, Argentina
Completed
Longmont, 80501, United States
Completed
Buenos Aires, C1280AEB, Argentina
Withdrawn
Rochester, 14618, United States
Completed
Florencio Varela, 1888, Argentina
Completed
Rosario, 2000, Argentina
Completed
Richmond, 23229, United States
Completed
Córdoba, 5000, Argentina
Withdrawn
Córdoba, 5000, Argentina
Completed
Fresno, 93720, United States
Completed
Tucumán, 4000, Argentina
Completed
Greenville, 29607, United States
Completed
Lake Oswego, 97035, United States
Completed
Carrollton, 75010, United States
Completed
Yukon, 73099, United States
Withdrawn
San Francisco, 94102, United States
Completed
Florencio Varela, 1888, Argentina
Completed
Colorado Springs, 80909, United States
Completed
Bridgeport, 06606, United States
Completed
San Miguel de Tucumán, 4000, Argentina
Completed
Birmingham, 35215, United States
Withdrawn
Detroit, 48202, United States
Completed
Charlottesville, 22911, United States
Completed
Hoover, 35216-5453, United States
Completed
North Massapequa, 11758, United States
Completed
Winchester, 22601, United States
Completed
Searcy, 72143, United States
Completed
Shreveport, 71105, United States
Completed
Orangeburg, 29118, United States
Completed
Harrisburg, 17110, United States
Completed
Jonesboro, 72401, United States
Completed
Columbus, 43235, United States
Completed
Salt Lake City, 84102, United States
Completed
Riverside, 92506, United States
Completed
Jackson, 38301, United States
Completed
DeLand, 32720, United States
Completed
Oklahoma City, 73120, United States
Completed
Spokane, 99202-1334, United States
Withdrawn
Detroit, 48202, United States
Withdrawn
Argentina

Primary Outcome

  • Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae
    date_rangeTime Frame:
    Days 1, 2, 3 of treatment
    enhanced_encryption
    Safety Issue:
    no

Secondary Outcome

  • Patient-reported symptom improvement using SNOT-16 questionnaire
    date_rangeTime Frame:
    Up to End of Treatment (Day 10-13)
    enhanced_encryption
    Safety Issue:
    no
  • Clinical Response
    date_rangeTime Frame:
    End of Treatment
    enhanced_encryption
    Safety Issue:
    yes
  • Bacteriological Response
    date_rangeTime Frame:
    End of Treatment
    enhanced_encryption
    Safety Issue:
    no
  • Activity Impairment Assessment questionnaire
    date_rangeTime Frame:
    Up to End of Treatment (Day 10-13)
    enhanced_encryption
    Safety Issue:
    no
  • Incidence of Premature Termination
    date_rangeTime Frame:
    Premature Termination
    enhanced_encryption
    Safety Issue:
    yes
  • Adverse Events Collection
    date_rangeTime Frame:
    Up to End of Treatment (Day 10-13)
    enhanced_encryption
    Safety Issue:
    yes

Trial design

Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial eradication and Key Symptom Relief in the treatment of Acute Bacterial Maxillary Sinusitis with Moxifloxacin 400 mg QD
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Non-randomized
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1